Amicus Therapeutics, Inc.

NasdaqGM:FOLD Stock Report

Market Cap: US$3.4b

Amicus Therapeutics Balance Sheet Health

Financial Health criteria checks 3/6

Amicus Therapeutics has a total shareholder equity of $132.5M and total debt of $388.9M, which brings its debt-to-equity ratio to 293.5%. Its total assets and total liabilities are $749.5M and $617.0M respectively.

Key information

293.5%

Debt to equity ratio

US$388.94m

Debt

Interest coverage ration/a
CashUS$260.06m
EquityUS$132.52m
Total liabilitiesUS$616.96m
Total assetsUS$749.48m

Recent financial health updates

Recent updates

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18

'Boring' Amicus Therapeutics Is Making Progress

Sep 29

Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector

Aug 16

Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Jul 02
Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Jun 06
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Feb 29

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Dec 19
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Jul 06
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

May 14
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Mar 23
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Dec 06
We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Aug 25
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Aug 10

Amicus Therapeutics Q2 2022 Earnings Preview

Aug 03

Financial Position Analysis

Short Term Liabilities: FOLD's short term assets ($461.7M) exceed its short term liabilities ($168.1M).

Long Term Liabilities: FOLD's short term assets ($461.7M) exceed its long term liabilities ($448.9M).


Debt to Equity History and Analysis

Debt Level: FOLD's net debt to equity ratio (97.2%) is considered high.

Reducing Debt: FOLD's debt to equity ratio has increased from 24.8% to 293.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FOLD has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FOLD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies